Tags

Type your tag names separated by a space and hit enter

Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.
Curr Med Res Opin 2017; 33(7):1191-1197CM

Abstract

BACKGROUND

The treatment of irritable bowel syndrome (IBS) is a challenge because its cause remains unknown. Previous clinical trials to examine the efficacy of probiotic Bifidobacterium infantis 35624 (B. infantis) in patients with IBS have shown inconsistent findings. This study aimed to assess the combined effect of B. infantis on reducing the symptom severity of IBS based on the published data.

METHODS

A meta-analysis was conducted using fixed-effect models to estimate the combined effect of B. infantis on primary outcomes, which included abdominal pain, bloating/distention, and bowel habit satisfaction. A systematic review was performed based on PubMed, Cochrane Library, and EMBASE databases to identify the randomized controlled trials comparing probiotic B. infantis with placebo in treating IBS symptoms, published up until 31 December 2016. The standardized mean difference (SMD) method was used to combine data since scales to measure the efficacy of probiotics were different among studies.

RESULTS

A total of five studies were identified as suitable for inclusion, including three studies with single probiotic B. infantis and two studies with composite probiotics containing B. infantis. Treatment with single probiotic B. infantis didn't impact on abdominal pain, bloating/distention, or bowel habit satisfaction among IBS patients. However, patients who received composite probiotics containing B. infantis had significantly reduced abdominal pain (SMD, 0.22; 95% CI, 0.03-0.41) and bloating/distention (SMD, 0.30; 95% CI, 0.04-0.56). After combining the data from six studies, the improvement of bloating/distention among IBS patients remained significant (SMD, 0.21; 95% CI, 0.07-0.35).

CONCLUSION

Composite probiotics containing B. infantis might be an effective therapeutic option for IBS patients, which could significantly alleviate the symptoms of IBS without significant adverse effects. However, the efficacy of single probiotic B. infantis on IBS has not been confirmed yet, which needs to be further validated by more large-sized randomized clinical trials.

Authors+Show Affiliations

a Department of Pharmacology and Toxicology , University of Louisville Health Sciences Center , Louisville , KY , USA.b Department of Mathematics , Illinois State University , Normal , IL , USA.c Center for Outcomes Research , University of Illinois College of Medicine at Peoria , Peoria , IL , USA. d Center for Pharmacoepidemiology & Pharmacoeconomic Research , University of Illinois College of Pharmacy at Chicago , IL , USA.c Center for Outcomes Research , University of Illinois College of Medicine at Peoria , Peoria , IL , USA.e Gastroenterology , OSF Saint Francis Medical Center , Peoria , IL , USA.c Center for Outcomes Research , University of Illinois College of Medicine at Peoria , Peoria , IL , USA.

Pub Type(s)

Journal Article
Meta-Analysis
Review
Systematic Review

Language

eng

PubMed ID

28166427

Citation

Yuan, Fuqiang, et al. "Efficacy of Bifidobacterium Infantis 35624 in Patients With Irritable Bowel Syndrome: a Meta-analysis." Current Medical Research and Opinion, vol. 33, no. 7, 2017, pp. 1191-1197.
Yuan F, Ni H, Asche CV, et al. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Curr Med Res Opin. 2017;33(7):1191-1197.
Yuan, F., Ni, H., Asche, C. V., Kim, M., Walayat, S., & Ren, J. (2017). Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Current Medical Research and Opinion, 33(7), pp. 1191-1197. doi:10.1080/03007995.2017.1292230.
Yuan F, et al. Efficacy of Bifidobacterium Infantis 35624 in Patients With Irritable Bowel Syndrome: a Meta-analysis. Curr Med Res Opin. 2017;33(7):1191-1197. PubMed PMID: 28166427.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. AU - Yuan,Fuqiang, AU - Ni,Huijuan, AU - Asche,Carl V, AU - Kim,Minchul, AU - Walayat,Saqib, AU - Ren,Jinma, Y1 - 2017/03/07/ PY - 2017/2/7/pubmed PY - 2018/1/5/medline PY - 2017/2/7/entrez KW - Bifidobacterium infantis 35624 KW - irritable bowel syndrome KW - meta-analysis KW - probiotic SP - 1191 EP - 1197 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 33 IS - 7 N2 - BACKGROUND: The treatment of irritable bowel syndrome (IBS) is a challenge because its cause remains unknown. Previous clinical trials to examine the efficacy of probiotic Bifidobacterium infantis 35624 (B. infantis) in patients with IBS have shown inconsistent findings. This study aimed to assess the combined effect of B. infantis on reducing the symptom severity of IBS based on the published data. METHODS: A meta-analysis was conducted using fixed-effect models to estimate the combined effect of B. infantis on primary outcomes, which included abdominal pain, bloating/distention, and bowel habit satisfaction. A systematic review was performed based on PubMed, Cochrane Library, and EMBASE databases to identify the randomized controlled trials comparing probiotic B. infantis with placebo in treating IBS symptoms, published up until 31 December 2016. The standardized mean difference (SMD) method was used to combine data since scales to measure the efficacy of probiotics were different among studies. RESULTS: A total of five studies were identified as suitable for inclusion, including three studies with single probiotic B. infantis and two studies with composite probiotics containing B. infantis. Treatment with single probiotic B. infantis didn't impact on abdominal pain, bloating/distention, or bowel habit satisfaction among IBS patients. However, patients who received composite probiotics containing B. infantis had significantly reduced abdominal pain (SMD, 0.22; 95% CI, 0.03-0.41) and bloating/distention (SMD, 0.30; 95% CI, 0.04-0.56). After combining the data from six studies, the improvement of bloating/distention among IBS patients remained significant (SMD, 0.21; 95% CI, 0.07-0.35). CONCLUSION: Composite probiotics containing B. infantis might be an effective therapeutic option for IBS patients, which could significantly alleviate the symptoms of IBS without significant adverse effects. However, the efficacy of single probiotic B. infantis on IBS has not been confirmed yet, which needs to be further validated by more large-sized randomized clinical trials. SN - 1473-4877 UR - https://www.unboundmedicine.com/medline/citation/28166427/Efficacy_of_Bifidobacterium_infantis_35624_in_patients_with_irritable_bowel_syndrome:_a_meta_analysis_ L2 - http://www.tandfonline.com/doi/full/10.1080/03007995.2017.1292230 DB - PRIME DP - Unbound Medicine ER -